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Abstract
The goal of this study is to determine whether patients with paraneoplastic cerebellar degeneration (PCD) and small-cell
lung cancer (SCLC) have a specific repertoire of antibodies, if SOX1 antibodies (SOX1-ab) can predict the presence of SCLC,
and if antibodies to cell surface antigens occur in this syndrome. Antibody analysis was done using immunohistochemistry
on rat brain, immunoblot with recombinant antigens, screening of cDNA expression libraries, and immunolabeling of live
neurons in 39 patients with PCD and SCLC. VGCC-ab were measured by RIA, and SOX1-ab, Hu-ab, and ZIC4-ab by
immunoblot. Lambert-Eaton myastenic syndrome (LEMS) was present in 10 of 23 patients with electrophysiological studies.
At least one antibody was detected in 72% of patients. The individual frequencies were: 49% SOX1-ab, 44% VGCC-ab, 31%
Hu-ab, and 13% ZIC4-ab. SOX1-ab occurred in 76% of patients with VGCC-ab and 27% of those without VGCC-ab
(p = 0.0036). SOX1-ab were not found in 39 patients with sporadic late-onset cerebellar ataxia, 23 with cerebellar ataxia and
glutamic acid decarboxylase antibodies, and 73 with PCD and cancer types other than SCLC (31 without onconeural
antibodies, 25 with Yo-ab , 17 with Tr-ab). Five patients (13%) had antibodies against unknown neuronal cell surface
antigens but none of them improved with immunotherapy. One serum immunoreacted against the axon initial segment of
neurons and another serum against ELKS1, a protein highly expressed in the cerebellum that interacts with the beta4-
subunit of the VGCC. In conclusion, 72% of patients with PCD and SCLC had one or more antibodies that indicate the
presence of this tumor. In these patients, VGCC-ab and SOX1-ab occur tightly associated. SOX1-ab are predictors of SCLC in
ataxia patients with a specificity of 100% and sensitivity of 49%. Unlike limbic encephalitis with SCLC, antibodies to cell
surface antigens other than VGCC-ab, are infrequent and do not predict response to treatment.
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The Purkinje cell is one of the most common targets of the
immune response that some patients with cancer built up against
antigens shared by the tumor and the nervous system [1]. The
death of Purkinje cells results in a pancerebellar syndrome called
paraneoplastic cerebellar degeneration (PCD) [1]. Small-cell lung
cancer (SCLC) is one of the most common tumors that associate
with PCD [2]. Whereas many patients (.80%) with other
paraneoplastic neurological syndromes and SCLC harbor Hu
antibodies (Hu-ab), the frequency of Hu-ab in PCD is low (23%)
[3]. Approximately, 40% of PCD patients with SCLC have
antibodies to voltage-gated calcium channels (VGCC), and some
also present clinical or neurophysiological evidence of Lambert-
Eaton myasthenic syndrome (LEMS) [3]. Up to 60% of patients
with LEMS and SCLC have SOX1-ab, a serologic marker of
SCLC [4].
Due to the frequent association of PCD with SCLC, and
sometimes with LEMS, we reasoned that determination of SOX1-
ab could also be useful to predict whether patients with suspected
PCD have an underlying SCLC. Moreover, patients with limbic
encephalitis and SCLC but without onconeural antibodies often
have antibodies against neuronal surface receptors, if this
paradigm also applies for PCD is unknown [5].
In the present study we analyzed the antibody repertoire in a
series of patients with PCD and SCLC, focusing on the frequency




We selected from our database, patients with the diagnosis of
PCD and SCLC. We specifically excluded patients who presented
with ataxia but quickly developed symptoms beyond cerebellar
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dysfunction. These patients were considered to have paraneoplas-
tic encephalomyelitis, which in contrast to PCD almost always
associates with Hu-ab [6]. The neurological disability was
evaluated by the modified Rankin scale as described [6,7]. The
clinical information was obtained from forms filled out by the
referring neurologists and telephone interviews.
Standard Protocol Approvals, Registrations, and Patient
Consents
Serum and CSF samples used in the study are deposited in the
collection of biological samples named "neuroinmunologı́a"
registered in the biobank of Institut d’ Investigació Biomèdica
August Pi i Sunyer (IDIBAPS), Barcelona, Spain. Considering that
many patients were dead at the time the study was performed and
the study is completely anonymous so no sample can be identified
to a particular patient, it was accepted to waive the specific written
informed consent from the patients or next of kin by the Comitè
Etic d’investigació Clı́nica (CEIC) of Hospital Clı́nic. Animal
handling procedures were approved by the Local Ethics Com-
mittee (99/1 University of Barcelona) and the Generalitat de
Catalunya (1094/99), in accordance with the Directive 86/609/
EU of the European Commission. The study as explained was
approved by the CEIC of Hospital Clı́nic.
Detection of anti-neuronal antibodies
Serum and CSF, when available, were evaluated for the
presence of onconeural (Hu, Yo, Ri, CV2, amphiphysin, Ma2,
Tr), anti-neuropil (NMDAR, AMPAR, GABABR, CASPR2,
LGI1, mGluR1 and mGluR5) or possible new antibodies by
immunohistochemistry on frozen sections of paraformaldehyde-
perfused or post-fixed rat cerebellum as reported [8]. Onconeural
antibody positivity was confirmed by a commercial immunoblot
(Ravo Diagnostika GmbH, Freiburg, Germany) and anti- neuropil
antibodies by a cell based assay using HEK293 cells transfected
with the appropriate plasmids, as previously described [9].
Antibodies against the subunit b4 and c2 of VGCC were detected
by immunofluorescence on HEK293 cells transfected with the
plasmids (MC201619 and SC312948; Origene, Rockville, Mary-
land, USA). Antibodies to P/Q type VGCC were measured by a
commercial radioimmunoassay (DLD Diagnostica GMBH, Ham-
burg, Germany). SOX1-ab and ZIC4-ab were determined using
nitrocellulose filters with mixed phage plaques (50% of plaques
from positive clones and 50% from irrelevant clones). Filters were
cut into pieces, each one incubated with different patient’s sera
(dilution 1:1000) and developed by an avidin-biotin immunoper-
oxidase technique as described [4].
To confirm the specificity of SOX1-ab in the diagnosis of PCD
associated with SCLC, SOX1-ab were also analyzed in the serum
of 31 patients with PCD and different cancer types, other than
SCLC, that did not harbor onconeural antibodies that could
confirm the diagnosis of PCD, 25 with PCD, breast or ovarian
cancer, and Yo-ab, 17 with PCD, Hodgkin disease, and Tr-ab, 39
patients with sporadic late-onset cerebellar ataxia, and 23 with
cerebellar ataxia and glutamic acid decarboxylase antibodies.
Primary cell culture and in vivo immunocytochemistry
Hippocampal neurons were obtained from E18 Wistar rat
embryos. Cells were enzymatically and mechanically disrupted
and resuspended in Neurobasal medium supplemented with B27
(Invitrogen, Carlsbad, CA, USA) [9]. Granular cell cultures were
prepared from dissected cerebella of 8-day-old Wistar rats and
processed equally as hippocampal neurons but using Neurobasal-
A medium containing 25 mM of KCl and supplemented with B27
[10]. Cells were plated in poly-L-lysine pre-coated P24 plates and
10 mM cytosine -D-arabinofuranoside (Sigma-Aldrich, St. Louis,
MO, USA) was added to the cultures 20 h after plating, to prevent
proliferation of non neuronal cells.
In the immunocytochemistry experiments, samples (1:5 CSF
dilution and 1:200 serum dilution) were incubated on live neurons
for 1 hour, then fixed with 4% paraformaldehyde and permea-
bilized with 0.3% Triton TX-100. Staining with anti-MAP2
antibody was performed in order to confirm the neuronal
specificity of the positive cells. Appropriate fluorescent secondary
antibodies were applied and the coverslips were mounted with
Vectashield with DAPI mounting media (Vector Laboratories,
Burlingame, CA, USA) and visualized with an Axio Imager M2
ZEISS microscope.
Screening of cDNA expression libraries
Uni-ZAP XR libraries from human cerebellum and human fetal
brain (Stratagene, La Jolla, CA) were immunoscreened with 10
PCD SCLC sera (4 patients with SOX1-ab and VGCC-ab, 4
seronegative, 1 with VGCC-ab and 1 with SOX1-ab), using
techniques previously reported [4]. Briefly, immunoscreening of
the cDNA library with sera (dilution 1:1000) was performed to
reach isolated positive plaques. Phage clones were subcloned in
pBluescript plasmid using the in vivo excision phage rescue
protocol (Stratagene, La Jolla, CA). Plasmid DNA was purified
with the QIAprep Spin Miniprep Kit (Qiagen, Santa Clarita, CA),
and sequenced with the DNA sequencer ABI 377 (Applied
Biosystems, Foster City, CA) using the Big Dye terminator ready
mix (Applied Biosystems). Positive clones were sequenced on both
strands. The human genome BLAST program (NCBI, NIH,
Bethesda, MD) was used to search for homologies.
Statistical Analysis
The correlation between SOX1-ab and VGCC-ab were




We identified 39 patients with PCD and SCLC. Median age of
the patients was 64 years (range: 47 to 85 years) and 34 were male.
PCD antedated the diagnosis of SCLC in 36 patients with a
median time of 2 months (range: 0.5 to 42 months). At the time of
PCD diagnosis 10 patients had LEMS and 13 did not (confirmed
by at least normal compound muscle action potentials in
electromyography (EMG) studies [11]). The rest of the 16 patients
did not refer symptoms of LEMS but no EMG studies were done.
Twenty seven patients received at least one full course (intravenous
immunoglobulins or steroids, or both) of immunotherapy (6
patients), chemotherapy (14) or both (7). No improvement or
stabilization with moderate-severe cerebellar dysfunction (Rankin
score . 3) occurred in 13 of the 21 patients (62%) who had
adequate follow-up. Three patients improved and 5 remained
stable with a Rankin score of 3 or less.
VGCC and onconeural antibodies: association with SOX1
antibodies
Seventy-two percent of patients had at least one of the indicated
antibodies. The individual frequencies of the antibodies were: 49%
SOX1-ab, 44% VGCC-ab, 31% Hu-ab, and 13% ZIC4-ab.
Twenty eight sera presented at least one antibody, and 11 were
negative (Figure 1). There was a clear correlation between SOX1-
ab and VGCC-ab. SOX1-ab were found in 76.5% of patients with
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VGCC-ab but in only 27.3% of those without VGCC-ab (Fisher
exact test p = 0.0036) (Figure 2). Positive VGCC-ab were found
in 9 (90%) of the 10 patients with LEMS and in 7 (54%) of the 13
without clinical or EMG evidence of LEMS. Similarly, SOX1-ab
were present in 80% of patients with LEMS and 38% of those
without LEMS. No associations were observed between VGCC-ab
or SOX1-ab and Hu-ab. None of the patients were positive for
onconeural antibodies, other than Hu, or presented well charac-
terized anti-neuropil antibodies. SOX1-ab were not detected in
the control series of 73 patients with PCD and different types of
cancers other than SCLC, 32 patients with sporadic late-onset
cerebellar ataxia, and 23 with cerebellar ataxia and glutamic acid
decarboxylase antibodies.
Identification of new antibodies
One serum with SOX1-ab also showed robust immunoreactiv-
ity against the axon initial segment of neurons in routine
immunohistochemical studies (Figure 3A). Screening of a human
cerebellum cDNA expression library with this serum failed to
identify the putative antigen. Another new antibody was identified
during the screening of cDNA libraries with one serum with
VGCC-ab. The target protein, called ELKS1, is highly abundant
in the cerebellum. We performed a specific phage screening assay
for the detection of ELKS1 but we could not find other positive
sera. PCD sera also did not show immunoreactivity with HEK293
cells transfected with the b4 or c2 auxiliary subunits of VGCC.
Five patients (12.8%) had antibodies against cell surface antigens
expressed in live, non-permeabilized hippocampal neurons (Figure
3B), but only 1 of them reacted with cerebellar granular neurons.
Discussion
In the current study we wanted to determine if patients with
PCD and SCLC had antibodies other than VGCC-ab that could
explain the cerebellar ataxia or at least to help in the diagnosis of
PCD. The isolated determination of VGCC-ab in a patient with
cerebellar ataxia with or without LEMS almost always confirms a
paraneoplastic origin because the clinical association of cerebellar
ataxia and LEMS very rarely occur in absence of cancer [12,13].
In addition, if the cerebellar ataxia is paraneoplastic and the
patient has VGCC-ab the underlying tumor is always a SCLC
[14].
To overcome this limitation, we analyzed the presence of
SOX1-ab, a serological marker of SCLC [15]. In our series of
PCD and SCLC we found that SOX1-ab were present in almost
50% of these patients. In contrast, SOX1-ab were not found in
serum of patients with PCD and other tumor types with or without
onconeural antibodies and in patients with cerebellar ataxia
without cancer. Our data indicate that SOX1-ab are good
predictors of an underlying SCLC in patients with cerebellar
ataxia. The frequency of SOX1-ab was even higher (76.5%) in
PCD patients with SCLC who also had VGCC-ab. This frequency
is similar to that reported in patients with LEMS and SCLC (67%)
[16]. Taken together, these data suggest that in patients with PCD
and SCLC, the co-occurrence of VGCC-ab and SOX1-ab is
Figure 2. Association of VGCC and SOX1 antibodies. Bar graph
representation of the correlation between SOX1-ab and VGCC-ab.
(Fisher exact test p = 0.0036).
doi:10.1371/journal.pone.0060438.g002
Figure 3. Identification of new antibodies. A. Antibodies against
hillock of the neurons of rat cerebellum. Immunohistochemistry on rat
sagittal cerebellum sections. Note the strong atypical reactivity of a PCD
SCLC serum against the hillock axon of the neurons, mainly in Purkinje
cells. Nuclei are counterstained with hematoxilin. B. Immunofluores-
cence on live hippocampal neurons. Hippocampal neurons incubated
with CSF 1/5 diluted of a PCD SCLC patient. Reactivity of the patient
against the membrane of the neuron is seen in green and MAP2
staining in red to ensure the neuronal lineage. Nuclei are seen blue with
DAPI. (objective 100x oil)
doi:10.1371/journal.pone.0060438.g003
Figure 1. Graphic representation of the SOX1, VGCC, Hu, and
ZIC4 antibodies in PCD associated with SCLC. Distribution of
SOX1-, VGCC-, Hu-, and ZIC4-ab in our patient cohort. Each row
represents a patient and when positive the cell is filled in color.
doi:10.1371/journal.pone.0060438.g001
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strongly associated even though 41% of PCD patients with
VGCC-ab of the current series did not have LEMS.
Previous studies showed that all patients with LEMS and SCLC
who had Hu-ab also had SOX1-ab [16]. Therefore, additional
testing for Hu-ab did not improve the diagnosis of paraneoplastic
LEMS [16]. However, the finding of the current study has
different implications. Whereas SOX1-ab, occurred in 48.7% of
patients with PCD, an additional 20% of patients had Hu-ab or
VGCC-ab. Overall, combining the testing of all 3 antibodies (all
commercially available) will identify almost 70% of patients with
PCD and SCLC. A few patients may have other onconeural
antibodies like ZIC4, CV2 or amphiphysin and all but ZIC4 are
routinely screened with the same kits commonly used to detect
Hu-ab.
We did not find other potentially useful antibodies in this series.
The serum of one patient showed reactivity with the axon initial
segment of large neurons. This antibody was previously reported
in a patient with encephalomyelitis and SCLC who developed
seizures and severe gait ataxia [17]. We previously identified this
immunoreactivity in a patient with SCLC without neurological
symptoms suggesting the antibody may be a marker of the
underlying SCLC (unpublished). Another patient had an antibody
against ELKS1, a protein predominantly expressed in Purkinje
cells [18]. Although ELKS1 co-immunoprecipitates with the b4
VGCC subunit, we could not identify antibodies reacting directly
with b4 or c2, which are VGCC subunits that are highly expressed
in the cerebellum [18,19]. Our study does not rule out the
possibility that the sera of these patients could have antibodies
against other VGCC subunits or interacting proteins. For
example, sera from patients with non-paraneoplastic LEMS react
more frequently with the domain IV of the alpha1A of VGCC
compared with patients with LEMS and SCLC [20].
The recent discovery of antibodies against neuronal surface
antigens has changed the concept that antibodies in CNS
paraneoplastic syndromes are only surrogate markers of the
underlying tumor. While in patients with limbic encephalitis and
SCLC approximately 50% have Hu-ab and the other 50% have
antibodies against synaptic proteins (mainly GABAB receptor) [5],
our study shows that in patients with PCD and SCLC the
occurrence of antibodies to cell surface proteins other than
VGCC-ab, is rare.
The practical implication of our study is that in patients with
cerebellar ataxia, SOX1-ab are good predictors of an associated
SCLC with a specificity of 100% and a sensitivity of 49%. In
addition, the combination of testing for SOX1-, VGCC-, and Hu-
ab identifies almost 70% of patients with PCD and SCLC. Given
that PCD usually develops before the diagnosis of the tumor, this
repertoire of antibodies is useful to establish that the cerebellar
syndrome is paraneoplastic, the underlying tumor is SCLC, and
the chance of neurological recovery is low.
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6. Graus F, Keime-Guibert F, Reñe R, Benyahia B, Ribalta T, et al. (2001) Anti-
Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain
124: 1138–1148.
7. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J (1988)
Interobserver agreement for the assessment of handicap in stroke patients.
Stroke 19: 604–607.
8. Ances BM, Vitaliani R, Taylor RA, Liebeskind DS, Voloschin A, et al. (2005)
Treatment-responsive limbic encephalitis identified by neuropil antibodies: MRI
and PET correlates. Brain 128: 1764–1777.
9. Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, et al. (2008) Anti-
NMDAR-receptor encephalitis: case series and analysis of the effects of
antibodies. Lancet Neurol 7: 1091–1098.
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